• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation.

作者信息

Gao Fei, Gao Yang, Luo Yi, Yu Jian, Fu Huarui, Lai Xiaoyu, Liu Lizhen, Ye Baodong, Lan Jianping, Song Xiaolu, Lu Ying, Chen Lieguang, Chen Yi, Yu Kang, Huang He, Shi Jimin, Zhao Yanmin

机构信息

Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.

出版信息

Am J Hematol. 2022 Feb 1;97(2):E44-E47. doi: 10.1002/ajh.26405. Epub 2021 Nov 24.

DOI:10.1002/ajh.26405
PMID:34778993
Abstract
摘要

相似文献

1
Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation.维奈托克联合去甲基化药物用于造血干细胞移植后复发的髓系恶性肿瘤的挽救治疗：一项代表浙江省血液和骨髓移植协作组的多中心回顾性研究
Am J Hematol. 2022 Feb 1;97(2):E44-E47. doi: 10.1002/ajh.26405. Epub 2021 Nov 24.
2
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.基于维奈克拉的疗法在异基因造血细胞移植后复发的急性髓系白血病中的挽救性应用。
Blood Cancer J. 2021 Mar 4;11(3):49. doi: 10.1038/s41408-021-00437-z.
3
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.异基因造血干细胞移植后髓系恶性肿瘤复发的治疗：维奈托克联合低甲基化药物的回顾性多中心分析-代表德国合作移植研究组。
Ann Hematol. 2021 Apr;100(4):959-968. doi: 10.1007/s00277-020-04321-x. Epub 2020 Nov 16.
4
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.先前接受过低甲基化剂治疗的继发性 AML 患者的一线治疗方法对其结局的影响。
J Hematol Oncol. 2022 Jan 29;15(1):12. doi: 10.1186/s13045-022-01229-z.
5
Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.维奈克拉联合供者淋巴细胞输注治疗异基因造血细胞移植后早期复发的急性髓系白血病：一项回顾性多中心研究。
Ann Hematol. 2021 Mar;100(3):817-824. doi: 10.1007/s00277-021-04398-y. Epub 2021 Jan 13.
6
Venetoclax for Refractory Myeloid Sarcoma.维奈托克用于治疗难治性髓系肉瘤
J Oncol Pract. 2019 Jul;15(7):413-415. doi: 10.1200/JOP.18.00753.
7
Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.维奈托克联合低甲基化药物治疗复发/难治性 AML 的真实世界结果。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(21):6557-6565. doi: 10.26355/eurrev_202111_27126.
8
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.5-阿扎胞苷和 venetoclax 后首次完全缓解的急性髓系白血病的异基因造血细胞移植：一项多中心回顾性研究。
Ann Hematol. 2022 Feb;101(2):379-387. doi: 10.1007/s00277-021-04693-8. Epub 2021 Oct 9.
9
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.维奈克拉治疗对低甲基化剂耐药的急性髓系白血病患者：一项多中心历史前瞻性研究。
Ann Hematol. 2019 Aug;98(8):1927-1932. doi: 10.1007/s00277-019-03719-6. Epub 2019 Jun 11.
10
Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.维奈托克联合低甲基化药物治疗复发/难治性急性髓系白血病：来自单中心的病例系列。
J BUON. 2021 Sep-Oct;26(5):2026-2032.

引用本文的文献

1
Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation.异基因干细胞移植后急性髓系白血病复发的新型治疗方法
Int J Mol Sci. 2023 Oct 9;24(19):15019. doi: 10.3390/ijms241915019.
2
Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Venetoclax 联合低甲基化药物治疗异基因造血干细胞移植后急性髓系白血病和骨髓增生异常综合征复发的疗效和安全性：系统评价和荟萃分析。
BMC Cancer. 2023 Aug 17;23(1):764. doi: 10.1186/s12885-023-11259-6.
3
Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.
异基因造血干细胞移植治疗 MDS 或 AML 的通科医生：表观遗传学治疗。
Front Immunol. 2022 Oct 4;13:1034438. doi: 10.3389/fimmu.2022.1034438. eCollection 2022.
4
Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering.新药与细胞工程时代异基因造血干细胞移植后急性髓系白血病复发的供体淋巴细胞输注优化
Front Oncol. 2022 Jan 27;11:790299. doi: 10.3389/fonc.2021.790299. eCollection 2021.